All Updates

All Updates

icon
Filter
Funding
Hepion Pharmaceuticals announces exercise of warrants; raises USD 2 million
AI Drug Discovery
Feb 16, 2024
This week:
Partnerships
Intuitive AI partner with Moda Center to implement Oscar Sort recycling technology
Waste Recovery & Management Tech
Yesterday
Management news
Funding
Minze Health raises USD 5.3 million in funding for product and market expansion; appoints new VP
Preventive Healthcare
Yesterday
Partnerships
Firefly Aerospace partners with True Anomaly for Space Force rapid-response mission launches
Space Travel and Exploration Tech
Yesterday
Funding
zkPass raises USD 12.5 million in Series A funding
Enterprise Blockchain Solutions
Yesterday
Partnerships
Ontada partners with Microsoft to process unstructured oncology data using Azure AI
Clinical Trial Technology
Yesterday
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
Listing
Pony.ai files for US IPO
Auto Tech
Yesterday
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
AI Drug Discovery

AI Drug Discovery

Feb 16, 2024

Hepion Pharmaceuticals announces exercise of warrants; raises USD 2 million

Funding

  • New Jersey-based AI therapeutic company Hepion Pharmaceuticals has raised USD 2 million through the immediate exercise of a Series B common stock purchase warrant of roughly one million shares at a revised price of USD 2.10 per share from USD 4.85 held by an institutional investor. The transaction is expected to close on February 21, 2024.

  • As part of the deal, Hepion will issue two additional warrants to purchase an aggregate of 1.5 million shares at USD 1.91 per share to the investor. These warrants are immediately exercisable; one permits exercise over five years, while the other allows exercise for eighteen months.

  • The funds will be used to advance research in chronic liver diseases.

  • Founded in 2013, Hepion Pharmaceuticals leverages its computational platform, AI-POWR, which combines AI, machine learning, and deep learning to accelerate the development of novel therapeutics for fibrotic diseases, including non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection. It analyzes large sets of proprietary preclinical and clinical datasets to identify the most appropriate drug targets and predict patient responses to therapies. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.